BrePco Biopharma
Private Company
Funding information not available
Overview
BrePco Biopharma is a commercial-stage, private biopharma company headquartered in Dublin, Ireland. It holds the EU marketing authorization for Neoatricon®, the only dopamine formulation specifically approved for pediatric use in the EU to treat hypotension in unstable neonates and children. The company is led by a small, experienced team with backgrounds in major pharma and appears to be in a revenue-generating phase, though its broader pipeline and long-term strategy beyond this single asset are not publicly disclosed. Its business model is centered on therapeutics, specifically addressing a critical unmet need in pediatric intensive care.
Technology Platform
Specialized pediatric drug formulation and delivery, focusing on ready-to-use, infant-suitable presentations of established critical care medicines.
Opportunities
Risk Factors
Competitive Landscape
Neoatricon® faces indirect competition from the widespread off-label use of extemporaneously compounded adult dopamine formulations, which are cheaper but carry higher error and contamination risks. It has no direct competitor with an EU-approved pediatric dopamine product, giving it a unique but commercially untested position. Broader competition includes other vasopressors (e.g., epinephrine, norepinephrine) used in pediatric shock, though these also often lack ready-to-use pediatric formulations.